More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$583023469
EPS
-0.51
P/E ratio
--
Price to sales
5.87
Dividend yield
--
Beta
2.430968
Previous close
$10.59
Today's open
$10.50
Day's range
$10.32 - $10.69
52 week range
$3.38 - $11.60
show more
CEO
Paul Badawi
Employees
186
Headquarters
Menlo Park, CA
Exchange
Nasdaq Global Select
Shares outstanding
55578977
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Sight Sciences, Inc. (SGHT) is a Great Momentum Stock: Should You Buy?
Does Sight Sciences, Inc. (SGHT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research • Nov 12, 2026

What Sight Sciences (SGHT) Said on Its Q3 Earnings Call
Sight Sciences NASDAQ: SGHT raised its full-year revenue outlook after reporting record third-quarter sales, driven by growth in its glaucoma business and increased adoption of its TearCare dry eye treatment.
MarketBeat • Nov 5, 2026

Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids
MENLO PARK, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, announced today that the Centers for Medicare & Medicaid Services (CMS) has established a new direct practice expense supply code for the single-use TearCare SmartLids® component of the TearCare® System (TearCare).
GlobeNewsWire • Nov 5, 2026

Sight Sciences to Present at Two Upcoming Investor Conferences
MENLO PARK, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at two upcoming conferences.
GlobeNewsWire • Nov 5, 2026

Sight Sciences, Inc. (SGHT) Q3 2026 Earnings Call Transcript
Sight Sciences, Inc. (SGHT) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance
MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the third quarter ended September 30, 2026.
GlobeNewsWire • Nov 4, 2026

Sight Sciences (SGHT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Sight Sciences (SGHT) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks Investment Research • Nov 5, 2026

Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Should You Buy?
Sight Sciences (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 28, 2026

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
MENLO PARK, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the third quarter ended September 30, 2026, after the market close on Wednesday, November 4, 2026. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
GlobeNewsWire • Oct 21, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Sight Sciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.